4.8 (361) In stock
Articles about SanBio
SanBio gets FDA RMAT designation for SB623 cell therapy
A Japanese Bioventure Company's Application of Stem Cell
Japan's regulatory framework: seeking to provide impetus to the
SanBio Awarded RMAT for SB623, a Modified Stem Cell Treatment for TBI
SanBio Granted Patent for Retinal Degeneration Stem Cell Treatment
Regenerative Medicine Companies Successfully Advance Stem Cell
World-Leading Development Team
CEO Message SanBio - Official Site
SanBio Receives $20 Million Grant From CIRM
Cells, Free Full-Text
SanBio: SB623, an Investigational Product, Granted Advanced
Commercialization of regenerative-medicine therapies
